Provided by Healio
October 23, 2013
SAN DIEGO — Kris Kowdley, MD, reports during the American College of Gastroenterology Annual Scientific Meeting that 12 weeks of sofosbuvir combination therapy was well tolerated and effective in patients with hepatitis C genotypes 1 through 6 infection.
Previously treated patients with HCV genotype 3 infection may benefit from extending therapy to 16 weeks, according to Kowdley, director of the Liver Center of Excellence at the Digestive Disease Institute of Virginia Mason Medical Center in Seattle.
Disclosure: Kowdley has received grant/research support from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead/Pharmasset, Intercept, Janssen, Merck, Mochida and Vertex; and has served on advisory boards for AbbVie, Gilead, Merck and Vertex, and as a scientific consultant at Novartis.
For more information:
Kowdley K. #38: Sofosbuvir + Ribavirin with or without Peginterferon Is Well-tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6. Presented at: the 2013 American College of Gastroenterology Annual Scientific Meeting; Oct. 11-16, San Diego.
No comments:
Post a Comment